Strides Pharma Science Limited (STAR) partners with Ascent Capital to unlock value in Pivot Path, realizing ₹1,000m while retaining 20% stake.
Strides Pharma Science Limited (STAR) reveals robust FY26 results with a 50% YoY growth in operational PAT and a 21% rise in Ex-US markets.